Actym Therapeutics Selected as Part of the BioCentury-BayHelix East-West Summit Class of 2022
Press Release
November 14, 2022
BERKELEY, CA — Nov. 14, 2022
Actym Therapeutics has been selected as part of the BioCentury-BayHelix East-West Summit Class of 2022. Dr. Christopher Thanos, Chief Executive Officer, has been invited to speak at the conference on Tuesday November 15, at 10:00 am PST. The title of Dr. Thanos’ presentation is “Design and Development of a Next-Generation Immuno-therapeutic Modality to Treat Solid Tumors”. Dr. Thanos will be available to answer questions at the conference.
For more information, please see: https://conferences.biocentury.com/china-healthcare-summit/presenting-companies
About Actym Therapeutics
Actym Therapeutics is a privately held, Berkeley-based biotechnology company focused on the discovery and development of transformational immunotherapies to treat cancer. The company has developed an avirulent, de-immunized, programmable, live immunotherapeutic modality called STACT (S. Typhimurium-Attenuated Cancer Therapy).
After IV dosing, STACT naturally and selectively expands in the extracellular milieu of the TME, an environment well-known to be hospitable for bacterial growth. Once there, it is naturally internalized by phagocytic, tumor-resident immune cells, facilitating combinatorial payload delivery to these cells. This approach enables the tumor-specific delivery of payloads (and combos) too toxic to be dosed systemically via conventional modalities, in a single therapeutic composition. Actym’s lead candidate, ACTM-838 leverages these capabilities and is being tested as a single agent and in combination with anti-PD1 therapy across multiple solid tumor types. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.
Media Contact:
Gwen Gordon Gwen Gordon Public Relations gwen@gwengordonpr.com
Actym Requests:
